A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer

Summary

Cabazitaxel has shown significant efficacy as second line chemotherapy after Docetaxel in men with metastatic castration resistant prostate cancer. This was demonstrated in the Tropic Study where Cabazitaxel showed survival superiority compared to mitoxantrone. Almost one in 4 patients treated with Cabazitaxel in this study required dose reductions or dose delays or stopped treatment due to toxicity. ConCab examines another scheduling for cabazitaxel to see if we can improve tolerability so that patients will receive a higher percentage of the treatment as planned.

Timeline

Start

2012-04

Primary completion

2015-10

Completion

2015-10

Drugs

Indications